| Mike Quirk |
Mike Quirk is currently the Chief Scientific Officer at SAGE Therapeutics, Inc. He previously worked as a Director at AstraZeneca Pharmaceuticals LP from 2012 to 2014. He received his undergraduate and doctorate degrees from the Massachusetts Institute of Technology. |
| Amy Schacterle |
Amy Schacterle is currently the Senior VP-Research & Development Strategy at SAGE Therapeutics, Inc. She previously worked as the Vice President-Regulatory Affairs at Sumitomo Pharma America, Inc. from 2004 to 2014. Dr. Schacterle holds a graduate and doctorate degree from the University of Virginia and an undergraduate degree from Rensselaer Polytechnic Institute. |
| Heinrich Schlieker |
Heinrich Schlieker is currently the Senior Vice President-Technical Operations at SAGE Therapeutics, Inc. Prior to this, he worked at Cubist, Inc. as the VP-Process Development & Manufacturing from 2011 to 2015. Schlieker received his undergraduate and doctorate degrees from Technische Universität Braunschweig. |
| Christopher Benecchi |
Christopher Benecchi is currently the Chief Business Officer at SAGE Therapeutics, Inc. Prior to his current position, he served as the Vice President & Global Head-Commercial Excellence at Alexion Pharmaceuticals, Inc. from 2019 to 2021. Before that, he was the Global Launch Head-Commercial & Medical Affairs at UCB, Inc. from 2011 to 2019. Mr. Benecchi holds an MBA from Duke University and completed his undergraduate studies at Colby College. |
| Matt Lasmanis |
Matt Lasmanis is currently the Director-Center for Social Norms at the University of Pennsylvania and the Chief Technology & Innovation Officer at SAGE Therapeutics, Inc. He was previously the Chief Innovation Officer & Vice President at GlaxoSmithKline LLC. He completed his undergraduate degree at Boston College. |
| Laura Gault |
Laura Gault is currently the Chief Medical Officer at SAGE Therapeutics, Inc. Prior to her current position, she worked as the Vice President at Alexion Pharmaceuticals, Inc. from 2019 to 2022 and as the Vice President-Neurology Clinic Development at Vertex Pharmaceuticals, Inc. from 2017 to 2019. Gault received her undergraduate degree from the University of Pittsburgh and her doctorate from Case Western Reserve University. |
| Kimi E. Iguchi |
Kimi E. Iguchi is currently the Director at Disarm Therapeutics, Inc. and the Chief Financial & Accounting Officer at SAGE Therapeutics, Inc. Iguchi's former jobs include Senior Director-Finance at Millennium Pharmaceuticals, Inc., Finance Manager at Biogen MA, Inc., Senior Manager-External Reporting at Biogen, Inc., Manager-Business Assurance at PricewaterhouseCoopers LLP, Chief Operating Officer-North America Region at Santhera Pharmaceuticals Holding AG, and Vice President-Finance at Cyberkinetics Neurotechnology Systems, Inc. Iguchi received an undergraduate degree from Drew University in 1984 and an MBA from Northeastern University in 1987. |
| Geno J. Germano |
Geno J. Germano is currently the President, Chief Executive Officer & Director at Elucida Oncology, Inc., Chairman at SAGE Therapeutics, Inc., Independent Director at Precision BioSciences, Inc., and a Member of the Group of 50. He previously held positions as a Director at The Medicines Co., Director at Biotechnology Innovation Organization, Director at Zoetis, Inc., Managing Director at Wyeth Australia Pty Ltd. and Wyeth New Zealand, Independent Director at Bioverativ, Inc., President & General Manager-Specialty Care at Wyeth LLC, Group President-Global Innovative Pharma Business at Pfizer Inc., President at Precigen, Inc., and Trustee at Albany College of Pharmacy & Health Sciences. Mr. Germano obtained his undergraduate degree from Albany College of Pharmacy & Health Sciences in 1983. |
| Erin E. Lanciani |
Erin E. Lanciani was the founder of Outsourcing Solutions, Inc. (founded in 1993) where she held the title of Partner from 1993 to 1999. She is currently the Director at Oxeia Biopharmaceuticals, Inc. and the Chief People & Experience Officer at SAGE Therapeutics, Inc. Ms. Lanciani's former positions include Executive Director-Human Resources at Bristol Myers Squibb Co. (2009-2014), Director-Human Resources at ViaCell, Inc. (2000-2001), Director-Human Resources at Bristol-Myers Squibb SARL, Human Resources Business Partner at Genzyme Corp. (1999-2000), Vice President-Human Resources at Adnexus (2006-2009), and Vice President-Human Resources at Therion Biologics Corp. (2002-2006). Ms. Lanciani obtained an undergraduate degree from Northeastern University. |
| Jeffrey M. Jonas |
Jeffrey M. Jonas is the founder of AVAX Technologies, Inc., Evogen, Inc., and Noema Pharma AG. He currently holds the position of Chairman at Noema Pharma AG. He is also a Director at Angiocrine Bioscience, Inc. and the Pharmaceutical Research & Manufacturers of America. Additionally, he serves as a Director at SAGE Therapeutics, Inc. and as an Independent Director at Generation Bio Co. Furthermore, he is a General Partner at Cure Ventures Management LP. In his former positions, Dr. Jonas served as an Independent Director at CARA Therapeutics, Inc. and Swedish Orphan Biovitrum AB. He was also an Independent Director at PureTech Health Plc and a Director at Decibel Therapeutics, Inc. From 2018 to 2024, he held the position of Director at Karuna Therapeutics, Inc. He previously served as the Chief Medical Officer & Executive Vice President at Forest Laboratories, Inc. from 2006 to 2007. He was an Executive Vice President at Ionis Pharmaceuticals, Inc. from 2007 to 2008. From 2008 to 2013, he was the President-Regenerative Medicine Division at Shire Plc. He also held the position of President at Shire Regenerative Medicine, Inc. Furthermore, he served as the Chief Resident at McLean Hospital, Inc. and Harvard Medical School. Prior to that, he was the Vice President-Research & Clinical Development at Upjohn Laboratories LLC from 1996 to 2013. Dr. Jonas obtained his undergraduate degree from Amherst College and his doctorate from Harvard Medical School. |
| Barry E. Greene |
Barry E. Greene is the founder and currently holds multiple positions. He founded VS, Inc. in 2014 and serves as the Chief Medical Officer. Currently, he is the President, Chief Executive Officer & Director at SAGE Therapeutics, Inc. since 2020. He is also a Director at Pharmaceutical Research & Manufacturers of America. Additionally, he is the Lead Independent Director at Karyopharm Therapeutics, Inc. since 2015 and an Independent Director at BCLS Acquisition Corp. since 2020. He serves as an Advisor at Longwood Fund Management LLC. Dr. Greene has held former positions as an Independent Director at Acorda Therapeutics, Inc. from 2007 to 2021. He was a Director at Intercept Pharmaceuticals, Inc. in 2011 and 2012. He also served as a Director at Ambrx, Inc. in 2014. From 2007 to 2012, he was a Director at Regulus Therapeutics, Inc. He held the position of Vice President-Marketing & Customer Services at AstraZeneca PLC from 1998 to 2000. In 2001 and 2003, he was the General Manager-Oncology Division at Millennium Pharmaceuticals, Inc. He served as the Chief Business Officer & Executive Vice President at Mediconsult.com, Inc. from 1999 to 2000. From 1986 to 1998, he was a Partner at Andersen Consulting LLP (GB) and later became a Partner at Accenture Ltd. He was the President of Alnylam Pharmaceuticals, Inc. from 2016 to 2020 and also held the position of Vice President-Strategic Integration at AstraZeneca Pharmaceuticals LP. Dr. Greene completed his undergraduate degree at the University of Pittsburgh. |
| Steven Marc Paul |
Steven Marc Paul founded Tal Medical, Inc. in 2010, where he is working as Chairman & Director and SAGE Therapeutics, Inc. in 2010, where he is working as Independent Director from 2014. Dr. Paul also founded Seaport Therapeutics, Inc., where he is working as Chairman. Dr. Paul also currently works at Foundation for the National Institutes of Health, Inc., as Chairman, Biotechnology Innovation Organization, as Director, Butler University, as Director, and various other companies. Dr. Paul also formerly worked at ImClone LLC, as Director, DemeRx, Inc., as Director, Alnylam Pharmaceuticals, Inc., as Independent Director from 2010 to 2022, and various other companies. Dr. Paul received his undergraduate degree in 1972 from Tulane University (Louisiana) and graduate degree and doctorate degree from Tulane University School of Medicine. |
| Jessica J. Federer |
Jessica J. Federer is currently serving as an Independent Director at SAGE Therapeutics, Inc., Director at HiDoc Technologies GmbH, Director at Maitri Holdings Corp., Managing Partner at Supernode Ventures, Board Member at Pluto Health, Inc., and Advisory Board Member at Angelini Ventures SpA. Previously, she served as the Managing Director, CEO & Advisor at Huma.AI, Inc., Chief Digital Officer at Bayer AG, and Venture Partner at Boston Millennia Partners. She also served as an Independent Director at Bloom Health Partners, Inc. Ms. Federer completed her undergraduate degree from George Washington University and earned an MBA from Yale School of Public Health. |
| James M. Frates |
James M. Frates is currently the Director at St. Francis House, Independent Director at SAGE Therapeutics, Inc., and Chief Financial Officer at Amylyx Pharmaceuticals, Inc. He previously worked as the Director at GPC Biotech AG and National Director at The Association of Bioscience Financial Officers. He was also the Vice President-Investment Banking at Robertson Stephens & Co. and the Chief Financial Officer & Senior Vice President at Alkermes Plc. Frates has served as Treasurer & Trustee at St. Paul's School and Roxbury Latin School. Frates holds an MBA degree from Harvard Business School and an undergraduate degree from Harvard College. |
| Michael F. Cola |
Michael F. Cola is currently the Chairman-Governors Board at The Boys & Girls Clubs of Philadelphia, Chairman at Phathom Pharmaceuticals, Inc., Independent Director at SAGE Therapeutics, Inc., and Trustee at Ursinus College. Previously, he served as the President, Chief Executive Officer & Director at Aevi Genomic Medicine, Inc., Chief Executive Officer & Director at Avalo Therapeutics, Inc., Chairman at SFN Group, Inc. (Massachusetts), Chairman at Clarient, Inc., Chairman at Laureate Biopharmaceutical Services, Inc., Independent Director at Vanda Pharmaceuticals, Inc., Independent Director at NuPathe, Inc., Director at Life Sciences Pennsylvania, President-Life Sciences Group at Safeguard Scientifics, Inc., Vice President-Global Clinical Operations at AstraZeneca PLC and Astra Merck, Inc., and President-Specialty Pharmaceuticals at Shire Plc. He holds a graduate degree from Drexel University and an undergraduate degree from Ursinus College. |
| George S. Golumbeski |
George S. Golumbeski is currently the Chairman at Carrick Therapeutics UK Ltd., Verseau Therapeutics, Inc., Actio Biosciences, Inc., Ananke Therapeutics, Inc., Shattuck Labs, Inc., Carrick Therapeutics Ltd., SAGE Therapeutics, Inc., Chroma Medicine, Inc., and Vertex Ventures HC. He is also the Deputy Chairman-Supervisory Board at MorphoSys AG and the Vice Chairman at National Audubon Society, Inc. Additionally, he serves as a Director at Corbus Pharmaceuticals, Inc., BlackThorn Therapeutics, Inc., Tusk Therapeutics Ltd., and Droia Ventures. In his former roles, Dr. Golumbeski served as the Chief Executive Officer at Nabriva Therapeutics GmbH from 2008 to 2009. He was also the President & Director at GRAIL LLC from 2018 to 2019. Furthermore, he held positions such as Chairman at Aura Biosciences, Inc. and BioSight Ltd., Director at Tizona Therapeutics, Inc., Pierce Biotechnology, Inc., Schwarz Pharma, Inc., EMD Pharmaceuticals, Inc., Acceleron Pharma, Inc., KSQ Therapeutics, Inc., and Enanta Pharmaceuticals, Inc., and Vice President & Director-Corporate Development at Schwarz Pharma, Inc. He was also the Senior Director-Licensing at EMD Pharmaceuticals, Inc. and the VP-Business Development, Licensing & Strategy at Novartis Oncology, Inc. Dr. Golumbeski's education includes a doctorate degree from the University of Wisconsin in 1985 and an undergraduate degree from the University of Virginia in 1979. |
| Elizabeth Barrett |
Elizabeth Barrett's current jobs include being the President, Chief Executive Officer & Director at UroGen Pharma Ltd., the President & Chief Executive Officer at UroGen Pharma, Inc., and an Independent Director at SAGE Therapeutics, Inc. She is also an Independent Director at Allogene Therapeutics, Inc. Her former jobs include being the Chief Executive Officer at Novartis Oncology, Inc. from 2018 to 2019. She also held positions at Medivation LLC (California), Lifesci Acquisition II Corp., Cephalon, Inc., Johnson & Johnson, Pfizer Inc., Ortho Biotech, Inc., and Veridex LLC. Ms. Barrett obtained an MBA from St. Joseph's University and an undergraduate degree from the University of Louisiana at Lafayette. |
